1.62
price down icon3.57%   -0.06
after-market After Hours: 1.64 0.02 +1.23%
loading
Zentalis Pharmaceuticals Inc stock is traded at $1.62, with a volume of 425.47K. It is down -3.57% in the last 24 hours and up +8.72% over the past month. Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
See More
Previous Close:
$1.68
Open:
$1.7
24h Volume:
425.47K
Relative Volume:
0.62
Market Cap:
$116.86M
Revenue:
-
Net Income/Loss:
$-292.19M
P/E Ratio:
-0.3568
EPS:
-4.54
Net Cash Flow:
$-208.41M
1W Performance:
+1.89%
1M Performance:
+8.72%
6M Performance:
+31.71%
1Y Performance:
-45.82%
1-Day Range:
Value
$1.61
$1.715
1-Week Range:
Value
$1.53
$1.84
52-Week Range:
Value
$1.01
$4.44

Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile

Name
Name
Zentalis Pharmaceuticals Inc
Name
Phone
(858) 263-4333
Name
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Name
Employee
166
Name
Twitter
@ZentalisP
Name
Next Earnings Date
2025-03-26
Name
Latest SEC Filings
Name
ZNTL's Discussions on Twitter

Compare ZNTL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ZNTL
Zentalis Pharmaceuticals Inc
1.62 121.19M 0 -292.19M -208.41M -4.54
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.37 104.55B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.95 60.36B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
557.73 59.84B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
799.56 49.07B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
327.03 35.16B 4.56B -176.77M 225.30M -1.7177

Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-12-24 Upgrade Wedbush Underperform → Neutral
Jun-20-24 Downgrade UBS Buy → Neutral
Jun-18-24 Downgrade Jefferies Buy → Hold
Jun-18-24 Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-18-24 Downgrade Wedbush Neutral → Underperform
Jun-18-24 Downgrade Wells Fargo Overweight → Equal Weight
Nov-08-23 Downgrade Wedbush Outperform → Neutral
Nov-07-23 Downgrade Leerink Partners Outperform → Market Perform
Jul-12-22 Initiated Cowen Outperform
Apr-06-22 Initiated Wells Fargo Overweight
Oct-07-21 Resumed Jefferies Buy
Sep-30-21 Initiated Stifel Buy
Sep-29-21 Initiated Oppenheimer Outperform
May-21-21 Initiated UBS Buy
Jan-20-21 Initiated Wedbush Outperform
Sep-29-20 Initiated Cantor Fitzgerald Overweight
Aug-27-20 Initiated H.C. Wainwright Buy
Apr-28-20 Initiated Guggenheim Buy
Apr-28-20 Initiated Jefferies Buy
Apr-28-20 Initiated Morgan Stanley Overweight
Apr-28-20 Initiated SVB Leerink Outperform
View All

Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News

pulisher
04:16 AM

Zentalis to present azenosertib data at cancer therapeutics conference - Investing.com India

04:16 AM
pulisher
04:15 AM

Zentalis Pharmaceuticals Announces Acceptance of Azenosertib Abstracts for Presentation at AACR-NCI-EORTC Conference - Quiver Quantitative

04:15 AM
pulisher
10:32 AM

Will Zentalis Pharmaceuticals Inc. stock keep outperforming rivalsJuly 2025 Analyst Calls & High Accuracy Swing Entry Alerts - newser.com

10:32 AM
pulisher
10:24 AM

How Zentalis Pharmaceuticals Inc. stock benefits from strong dollarGap Up & Stepwise Entry and Exit Trade Signals - newser.com

10:24 AM
pulisher
09:44 AM

How currency fluctuations impact Zentalis Pharmaceuticals Inc. stockWall Street Watch & Risk Managed Investment Signals - newser.com

09:44 AM
pulisher
Oct 12, 2025

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress - ADVFN Ltd

Oct 12, 2025
pulisher
Oct 12, 2025

Can Zentalis Pharmaceuticals Inc. hit a new high this monthTrade Risk Summary & Weekly High Potential Stock Alerts - newser.com

Oct 12, 2025
pulisher
Oct 11, 2025

Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Wealth Enhancement Advisory Services LLC - Defense World

Oct 11, 2025
pulisher
Oct 10, 2025

What institutional flow reveals about Zentalis Pharmaceuticals Inc.Market Sentiment Review & Community Trade Idea Sharing - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Weiss Ratings Reaffirms Sell (E+) Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World

Oct 10, 2025
pulisher
Oct 09, 2025

What earnings revisions data tells us about Zentalis Pharmaceuticals Inc.Weekly Trade Report & Entry Point Confirmation Alerts - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Full technical analysis of Zentalis Pharmaceuticals Inc. stockJuly 2025 Review & AI Optimized Trade Strategies - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Using data filters to optimize entry into Zentalis Pharmaceuticals Inc.Watch List & Verified Technical Trade Signals - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

Zentalis Pharmaceuticals' (ZNTL) "Sell (E+)" Rating Reiterated at Weiss Ratings - MarketBeat

Oct 08, 2025
pulisher
Oct 06, 2025

Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock - Yahoo Finance

Oct 06, 2025
pulisher
Oct 06, 2025

Key metrics from Zentalis Pharmaceuticals Inc.’s quarterly dataQuarterly Market Summary & Stepwise Swing Trade Plans - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Short interest data insights for Zentalis Pharmaceuticals Inc.2025 Fundamental Recap & Verified Short-Term Plans - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Pattern recognition hints at Zentalis Pharmaceuticals Inc. upsideJuly 2025 Review & Target Return Focused Picks - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

How to build a dashboard for Zentalis Pharmaceuticals Inc. stockMarket Activity Report & Smart Swing Trading Techniques - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

Positive week for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) institutional investors who lost 48% over the past year - simplywall.st

Oct 03, 2025
pulisher
Oct 02, 2025

What analysts say about Zentalis Pharmaceuticals Inc stockDebt-to-Equity Ratio Analysis & Ride the Trends That Billionaires Follow - earlytimes.in

Oct 02, 2025
pulisher
Oct 01, 2025

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 01, 2025
pulisher
Oct 01, 2025

400,000 Stock Options at $1.54: Zentalis Pharmaceuticals Welcomes New Chief Legal Officer with Major Grant - Stock Titan

Oct 01, 2025
pulisher
Sep 25, 2025

Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Goldman Sachs Group Inc. - Defense World

Sep 25, 2025
pulisher
Sep 25, 2025

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Sep 25, 2025

Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Zentalis Pharmaceuticals Inc Stock (ZNTL) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Bruns Ingmar
Chief Medical Officer
Feb 06 '25
Buy
2.28
20,000
45,656
36,629
$84.73
price up icon 1.11%
$22.93
price up icon 7.40%
$32.68
price up icon 2.73%
$102.30
price up icon 0.24%
$163.94
price up icon 0.99%
biotechnology ONC
$327.03
price up icon 2.16%
Cap:     |  Volume (24h):